Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Carbylan Therapeutics Investigated After Violation of Federal Securities Laws

By PR Newswire | January 20, 2017

Pittsburgh Law Office of Alfred G. Yates Jr., PC announces investigation of Carbylan Therapeutics, Inc. (CBYL), currently known as KalVista Pharmaceuticals, Inc. (KALV).

Law Office of Alfred G. Yates Jr., PC is investigating whether certain officers and directors of Carbylan Therapeutics, Inc. violated federal securities laws in connection with its initial public offering (IPO). Carbylan Therapeutics is a specialty pharmaceutical company that develops and commercializes novel and proprietary combination therapies.

On April 9, 2015, Carbylan’s stock traded as high as $6.58, the same day the company sold 13 million shares of stock in its initial public stock offering (IPO), raising $65.0 million in new capital. However, since the IPO, Carbylan’s stock has tumbled, falling from its high of $9.22 on June 8, 2015 to close at $0.49 on September 22, 2016.

On February 1, 2016 Carbylan stock plunged nearly 50 percent after the company disclosed top-line results from a Phase 3 trial, COR1.1. Then, in April 2016, Carbylan announced that it was suspending further clinical development of its pain relief product, Hydros–TA, and it is actively pursuing a merger or acquisition of the company. In concurrence, Carbylan also announced an immediate reduction in its workforce of 14 of its current 17 employees to preserve capital.

On May 12, 2016, the company reported net losses of approximately $6.6 million and $5.2 million in the three months ended March 31, 2016 and 2015, respectively.

As a result of a merger completed on November 22, 2016, Carbylan changed its name to KalVista Pharmaceuticals, Inc., an commenced trading under the symbol “KALV”.

(Source: PR Newswire)

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE